Novartis hands PeptiDream $180M upfront to extend radiopharma discovery pact
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds. The Japanese biotech, which has a long list of drug development partners, will get